Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

Abstract Background We have previously shown that podocalyxin-like protein (PODXL) is a prognostic biomarker for poor survival in gastric and esophageal adenocarcinoma treated with surgery up-front. The aim of the present study was to assess PODXL expression in tumors from patients treated with neoa...

Full description

Bibliographic Details
Main Authors: David Borg, Anna H. Larsson, Charlotta Hedner, Björn Nodin, Anders Johnsson, Karin Jirström
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Journal of Translational Medicine
Subjects:
Esophageal adenocarcinoma
Gastric adenocarcinoma
Neoadjuvant chemotherapy
PODXL
Online Access:http://link.springer.com/article/10.1186/s12967-018-1668-3

Internet

http://link.springer.com/article/10.1186/s12967-018-1668-3

Similar Items